GPT and metabolic syndrome: The pronounced improvements in serum lipid profiles (23% reduction in total cholesterol, 18% in TG, and 27% in LDL-cholesterol) and liver function markers (AST, ALT) further emphasize CRBE’s potential as a multifunctional agent addressing the metabolic syndrome cluster.